Clinical Trial Update: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on OnabotulinumtoxinA for urinary incontinence due to neurogenic detrusor overactivity in non-catheterizing MS patients; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Neurogenic Bladder
• Urinary Incontinence

Drugs mentioned

• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: Allergan | Conditions: Urinary Incontinence, Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2016-03-22